Litcius/Paper detail

LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44

A. Lambert, Olivier Bouché, Ahmet Ayav, J-B. Bachet, Lilian Schwarz, G. Piessen, V. Vendrely, Valérie Laurent, Emilie Thibaudeau, Laurent Miglianico, Yves Rinaldi, P. Hammel, T. Conroy

2024Annals of Oncology20 citationsDOIOpen Access PDF

Topics & Concepts

MedicineFOLFIRINOXPancreatic cancerOncologyInternal medicineCancerColorectal cancerOxaliplatinPancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsHepatocellular Carcinoma Treatment and Prognosis
LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44 | Litcius